1. Home
  2. MEIP vs EP Comparison

MEIP vs EP Comparison

Compare MEIP & EP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • EP
  • Stock Information
  • Founded
  • MEIP 2000
  • EP 1983
  • Country
  • MEIP United States
  • EP United States
  • Employees
  • MEIP N/A
  • EP N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • EP Oil & Gas Production
  • Sector
  • MEIP Health Care
  • EP Energy
  • Exchange
  • MEIP Nasdaq
  • EP Nasdaq
  • Market Cap
  • MEIP 153.9M
  • EP 171.5M
  • IPO Year
  • MEIP 2003
  • EP N/A
  • Fundamental
  • Price
  • MEIP $3.00
  • EP $4.50
  • Analyst Decision
  • MEIP
  • EP
  • Analyst Count
  • MEIP 0
  • EP 0
  • Target Price
  • MEIP N/A
  • EP N/A
  • AVG Volume (30 Days)
  • MEIP 790.3K
  • EP 19.8K
  • Earning Date
  • MEIP 09-23-2025
  • EP 08-13-2025
  • Dividend Yield
  • MEIP N/A
  • EP N/A
  • EPS Growth
  • MEIP N/A
  • EP N/A
  • EPS
  • MEIP N/A
  • EP N/A
  • Revenue
  • MEIP N/A
  • EP $39,170,178.00
  • Revenue This Year
  • MEIP N/A
  • EP N/A
  • Revenue Next Year
  • MEIP N/A
  • EP N/A
  • P/E Ratio
  • MEIP N/A
  • EP N/A
  • Revenue Growth
  • MEIP 33.76
  • EP N/A
  • 52 Week Low
  • MEIP $1.46
  • EP $3.76
  • 52 Week High
  • MEIP $9.00
  • EP $8.12
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 26.36
  • EP 42.61
  • Support Level
  • MEIP $3.85
  • EP $4.75
  • Resistance Level
  • MEIP $5.50
  • EP $5.00
  • Average True Range (ATR)
  • MEIP 0.37
  • EP 0.35
  • MACD
  • MEIP -0.20
  • EP -0.02
  • Stochastic Oscillator
  • MEIP 3.10
  • EP 8.28

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About EP Empire Petroleum Corporation

Empire Petroleum Corp is a conventional oil and natural gas producer with a main focus in the United States onshore. The company possesses long-life, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana and Texas. It has production from operated and non-operated wells in Lea County in New Mexico, Bottineau, Renville, Burke, and McKenzie Counties in North Dakota, Richland County in Montana, St. Landry, Beauregard Parishes in Louisiana and Houston, Leon and Madison Counties in Texas.

Share on Social Networks: